Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2020 - 2022)

Atea Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $686.6 million for Q3 2022.

  • Quarterly results put Liabilities and Shareholders Equity at $686.6 million for Q3 2022, down 18.6% from a year ago — trailing twelve months through Dec 2022 was $2.1 billion (down 36.97% YoY), and the annual figure for FY2021 was $772.9 million, down 10.51%.
  • Liabilities and Shareholders Equity for Q3 2022 was $686.6 million at Atea Pharmaceuticals, down from $694.3 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AVIR hit a ceiling of $871.5 million in Q2 2021 and a floor of $110.1 million in Q3 2020.
  • Median Liabilities and Shareholders Equity over the past 3 years was $772.9 million (2021), compared with a mean of $711.2 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 666.08% in 2021 and later fell 20.33% in 2022.
  • Atea Pharmaceuticals' Liabilities and Shareholders Equity stood at $863.6 million in 2020, then decreased by 10.51% to $772.9 million in 2021, then fell by 11.17% to $686.6 million in 2022.
  • The last three reported values for Liabilities and Shareholders Equity were $686.6 million (Q3 2022), $694.3 million (Q2 2022), and $717.2 million (Q1 2022) per Business Quant data.